Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin Starts Japan PIII of Lumicef for Palmoplantar Pustulosis
August 27, 2019
- Nasonex Authorized Generic Now Available
August 26, 2019
- Sawai Aims to See “Branded Generics” Account for One-Third of Its Product Lineup in US in 2024
August 26, 2019
- Astellas/Pfizer’s Xtandi Given FDA’s Priority Review for Hormone-Sensitive Prostate Cancer
August 23, 2019
- Pfizer Launches Herceptin Biosimilar in Japan
August 23, 2019
- Price Revision Rates in October Re-Pricing Vary in Crowded DPP-4 Class: Survey
August 22, 2019
- Celltrion/Nippon Kayaku Herceptin Biosimilars Get OK for New Breast Cancer Dosing Schedule
August 22, 2019
- GSK’s Daprodustat Reaches 1st NDA Filing, in Japan
August 22, 2019
- NEDO to Subsidize Development of FunPep’s Antibody-Inducing Peptide for Psoriasis Treatment
August 22, 2019
- Tomita Pharmaceutical Invests in Wearable Medical Device Startup
August 22, 2019
- Frontloaded Price Cuts before Regular April Revision Hurts, Say Drug Makers
August 21, 2019
- Teva Takeda to License 10 APIs/20 Products from Sawai as It Plans to Shutter In-House Plants
August 21, 2019
- Big 3 Generic Players Braced for Average 9.2% Price Cut in October Re-Pricing
August 20, 2019
- Tax Hike Re-Pricing Slams Small Pharma and Gx Players, Impact Milder for Big Firms: Survey
August 20, 2019
- Sumitomo Dainippon Flip-Plops on Sales Force Cutback as It Ramps Up Diabetes Push
August 19, 2019
- Pharmacist Average Monthly Salary Down 9,636 Yen: Survey
August 19, 2019
- Osaka Univ. Spinout StemRIM Makes Tepid TSE Debut
August 16, 2019
- Towa Starts Joint Research with National CV Center on Disease Prevention, Healthy Life Expectancy Extension
August 16, 2019
- AstraZeneca Japan Adjusts Company Rules for Same-Sex, Common-Law Couples
August 16, 2019
- Otsuka Rings Up Double-Digit Growth in H1 Pharma Sales
August 9, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…